罗伊乳杆菌
结直肠癌
肠道菌群
癌症
微生物群
代谢物
生物
癌症研究
失调
癌变
微生物学
乳酸菌
免疫学
细菌
生物化学
生物信息学
遗传学
作者
Hannah N. Bell,Ryan Rebernick,Joshua Goyert,Rashi Singhal,Miljan Kuljanin,Samuel A. Kerk,Wesley Huang,Nupur K. Das,Anthony Andren,Sumeet Solanki,Shannon L. Miller,Peter K. Todd,Eric R. Fearon,Costas A. Lyssiotis,Steven P. Gygi,Joseph D. Mancias,Yatrik M. Shah
出处
期刊:Cancer Cell
[Cell Press]
日期:2021-12-23
卷期号:40 (2): 185-200.e6
被引量:141
标识
DOI:10.1016/j.ccell.2021.12.001
摘要
Microbial dysbiosis is a colorectal cancer (CRC) hallmark and contributes to inflammation, tumor growth, and therapy response. Gut microbes signal via metabolites, but how the metabolites impact CRC is largely unknown. We interrogated fecal metabolites associated with mouse models of colon tumorigenesis with varying mutational load. We find that microbial metabolites from healthy mice or humans are growth-repressive, and this response is attenuated in mice and patients with CRC. Microbial profiling reveals that Lactobacillus reuteri and its metabolite, reuterin, are downregulated in mouse and human CRC. Reuterin alters redox balance, and reduces proliferation and survival in colon cancer cells. Reuterin induces selective protein oxidation and inhibits ribosomal biogenesis and protein translation. Exogenous Lactobacillus reuteri restricts colon tumor growth, increases tumor reactive oxygen species, and decreases protein translation in vivo. Our findings indicate that a healthy microbiome and specifically, Lactobacillus reuteri, is protective against CRC through microbial metabolite exchange.
科研通智能强力驱动
Strongly Powered by AbleSci AI